BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gemcitabine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gemcitabine\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06156514-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06156514)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Evaluation of Concomitant Chemo-
 radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouter
 ine Cancer\nEstimated primary completion: 30 November 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06156514
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02889666-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 1 readout est. (NCT02889666)
DESCRIPTION:Gemcitabine\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A R
 andomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell 
 Lung Cancer\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02889666
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03017326-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT03017326)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Paediatric Hepatic International
  Tumour Trial\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03017326
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115163-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT04115163)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclita
 xel for the Treatment of Metastatic Pancreatic Cancer\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04115163
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024734-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05024734)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Guiding Instillation in Non Musc
 le-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organo
 ids\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05024734
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05764044-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT05764044)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Adjuvant Chemotherapy in cfHPV-D
 NA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Canc
 er\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05764044
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05975307-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05975307)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Treating Muscle-invasive Bladder
  Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Che
 moradiation\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05975307
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014943-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07014943)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: High-Dose Gemcitabine\, Busulfan
 \, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphom
 a\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07014943
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492915-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06492915)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic D
 uctal Adenocarcinoma\nEstimated primary completion: 28 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06492915
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06255210-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06255210)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Efficacy and Safety of Induction
  Chemotherapy for Olfactory Neuroblastoma (ESICON)\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06255210
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03533582-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT03533582)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Cisplatin and Combination Chemot
 herapy in Treating Children and Young Adults With Hepatoblastoma or Liver 
 Cancer After Surgery\nEstimated primary completion: 31 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03533582
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06494514-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Gemcitabine: Phase na readout est. (NCT06494514)
DESCRIPTION:Gemcitabine\, phase na\, Pancreatic Cancer.\nStudy: NALIRIFOX C
 ombined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Seq
 uential Radiotherapy as First-line Treatment of Locally Advanced Pancreati
 c Cancer\nEstimated primary completion: 1 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06494514
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: Durvalumab a
 nd Tremelimumab in Combination With Propranolol and Chemotherapy for Treat
 ment of Advanced Hepatopancreabiliary Tumors (BLOCKED)\nEstimated primary 
 completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05451043
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Gemcitabine\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05825066-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05825066)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced
  Pancreatic Adenocarcinoma\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05825066
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163273-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07163273)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Met
 astatic Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: 20
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7163273
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235203-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06235203)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Neoadjuvant vs Adjuvant in Local
 ly Advanced Recurrent NPC\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06235203
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064863-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT07064863)
DESCRIPTION:Gemcitabine\, phase 1/2.\nStudy: A Tumor Immune Biomarker Guide
 d Approach for Improving Response to BCG in Patients With High-risk NMIBC.
 \nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07064863
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488222-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06488222)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Intravesical Gemcitabine and Doc
 etaxel for Low Grade Intermediate Risk Bladder Cancer\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06488222
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492225-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07492225)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Neoadjuvant Chemotherapy Before 
 Surgery vs Surgery Alone for UTUC: A Randomized Trial\nEstimated primary c
 ompletion: 15 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07492225
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423326-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06423326)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Gemcitabine\, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for
  Patients With Resectable or Borderline Resectable Pancreatic Cancer\nEsti
 mated primary completion: 31 August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06423326
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184021-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07184021)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Neoadjuvent Dose-dense Gemcitabi
 ne and Cisplatin In Muscle Invasive Bladder Cancer\nEstimated primary comp
 letion: September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07184021
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03492671-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT03492671)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: Testing the 
 Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surg
 ery in Localized Pancreatic Cancer\nEstimated primary completion: October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0349267
 1
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07189793-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07189793)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Toripalimab ± Sequential Intrav
 esical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk 
 NMIBC: Open-Label Randomized Phase 2 Study\nEstimated primary completion: 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcita
 bine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07189793
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04179162-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT04179162)
DESCRIPTION:Gemcitabine\, phase 1/2.\nStudy: Bacillus Calmette-Guérin (BCG
 ) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Ca
 ncer That Came Back After BCG Treatment\nEstimated primary completion: Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4179162
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019220-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07019220)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Chemoablation for Low-Grade Blad
 der Cancer\nEstimated primary completion: November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07019220
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03093909-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Gemcitabine: Phase 1 readout est. (NCT03093909)
DESCRIPTION:Gemcitabine\, phase 1.\nStudy: Study of Aerosol Gemcitabine in 
 Patients With Solid Tumors and Pulmonary Metastases\nEstimated primary com
 pletion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03093909
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04574960-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT04574960)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Neoadjuvant Upper Tract Invasive
  Cancer Trial (NAUTICAL)\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04574960
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026905-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05026905)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: A Phase II R
 andomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1
 /LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pan
 creatic Cancer\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05026905
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115499-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06115499)
DESCRIPTION:Gemcitabine\, phase 2/3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treat
 ment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cance
 r\nEstimated primary completion: 1 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06115499
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683315-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT04683315)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: PurIST Class
 ification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profi
 ling of EUS Aspiration Samples\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0468331
 5
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229496-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 1 readout est. (NCT06229496)
DESCRIPTION:Gemcitabine\, phase 1\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Dose Escalation and Dose Expansion Study of GAS in Subjects With Metast
 atic Pancreatic Adenocarcinoma\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0622949
 6
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06388720-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06388720)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: The Clinical Effectiveness and S
 afety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06388720
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06567600-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06567600)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Low-dose Gemcitabine and Cisplat
 in and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06567600
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Study of Precision Treatment for
  Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 emcitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06692491
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07529483-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07529483)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Endoscopic Ultrasound-Guided Che
 moablation for the Treatment of Pancreatic Cystic Neoplasms\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07529483
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897565-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07897565)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Safety and Efficacy of Gemcitabi
 ne\, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Ad
 vanced Biliary Tract Cancer Intolerant to Conventional Chemotherapy\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07897565
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928362-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase na readout est. (NCT07928362)
DESCRIPTION:Gemcitabine\, phase na\, Pancreatic Cancer.\nStudy: A Multicent
 er\, Prospective Single-arm Study of Multimodal Thermal Therapy Combined W
 ith Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreati
 c Cancer\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07928362
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06167057-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Gemcitabine: Phase na readout est. (NCT06167057)
DESCRIPTION:Gemcitabine\, phase na.\nStudy: POST URS Chemotherapy Instillat
 ion\nEstimated primary completion: 30 January 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06167057
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822010-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06822010)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: SeqUential GeMcitabine and MITom
 ycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carc
 inoma\nEstimated primary completion: 1 April 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06822010
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076212-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07076212)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Evaluating NALIRIFOX vs Modified Gemcitabine\, Nab-Paclitaxel and Cispl
 atin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarc
 inoma\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07076212
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198451-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT07198451)
DESCRIPTION:Gemcitabine\, phase 2/3.\nStudy: Efficacy of Gemcitabine Submuc
 osal Injection for Preventing Recurrence in Intermediate- and High-Risk No
 n-Muscle-Invasive Bladder Cancer: A Randomized Trial\nEstimated primary co
 mpletion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 emcitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07198451
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418931-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07418931)
DESCRIPTION:Gemcitabine\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A M
 ulticenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy\, Sel
 ected on the Basis of Baseline Cytidine Deaminase Activity\, in Advanced S
 quamous Non-small Cell Lung Cancer\nEstimated primary completion: May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07418931
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000084-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT07000084)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Testing the Addition of an Anti-
 Cancer Drug\, Gemcitabine\, to Usual Treatment (BCG Alone) in People Whose
  Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Ther
 apy\nEstimated primary completion: 5 June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07000084
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228079-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06228079)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Adjuvant vs Surgery Only in Earl
 y-stage Recurrent NPC\nEstimated primary completion: 30 June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06228079
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07945782-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT07945782)
DESCRIPTION:Gemcitabine\, phase 1/2\, Pancreatic Cancer.\nStudy: A Phase I/
 II Single-Arm\, Open-Label\, Exploratory Study Evaluating the Safety and E
 fficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine
  and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer\nE
 stimated primary completion: 30 June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07945782
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04559139-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT04559139)
DESCRIPTION:Gemcitabine\, phase 2/3.\nStudy: Comparison of Chemotherapy Bef
 ore and After Surgery Versus After Surgery Alone for the Treatment of Gall
 bladder Cancer\nEstimated primary completion: 1 July 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04559139
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043270-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07043270)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: 24BRO681 : Alternating Gnp and m
 FOLFIRINOX for BR-PDAC\nEstimated primary completion: 1 July 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07043270
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693959-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT07693959)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Neoadjuvant RC48 Plus Gemcitabin
 e in HER2-Expressing MIBC\nEstimated primary completion: 1 July 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07693959
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05800587)
DESCRIPTION:Gemcitabine\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Dos
 e Attenuated Chemotherapy in Compromised Patients With Lung Cancer\nEstima
 ted primary completion: 1 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020065-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07020065)
DESCRIPTION:Gemcitabine\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Red
 uced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Mono
 therapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC 
 With PD-L1 <50%\nEstimated primary completion: September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07020065
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04535271-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT04535271)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Metronomic Trabectedin\, Gemcita
 bine\, and Dacarbazine for Soft Tissue Sarcoma\nEstimated primary completi
 on: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04535271
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883135-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07883135)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Bispecific Antibody-Based Holdin
 g/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas\nEstimated 
 primary completion: 1 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07883135
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01878617-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT01878617)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: A Clinical and Molecular Risk-Di
 rected Therapy for Newly Diagnosed Medulloblastoma\nEstimated primary comp
 letion: 13 October 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT01878617
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06923475-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281106
DTEND;VALUE=DATE:20281107
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06923475)
DESCRIPTION:Gemcitabine\, phase 2/3.\nStudy: Neoadjuvant Gemcitabine and Ci
 splatin in Combination With Perioperative Pembrolizumab Versus Upfront Sur
 gery for Patients With Primary Resectable and Borderline Resectable Perihi
 lar and Distal Cholangiocarcinoma\nEstimated primary completion: 6 Novembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06923
 475
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06037980-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06037980)
DESCRIPTION:Gemcitabine\, phase 2/3.\nStudy: CisPlatin plUs Gemcitabine and
  Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resecti
 on in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk fo
 r Recurrence\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06037980
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888621-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07888621)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Glofitamab Plus Gemcitabine and 
 Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Centra
 l Nervous System Lymphoma\nEstimated primary completion: December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07888621
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902713-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07902713)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Becotatug Vedotin Plus Gemcitabi
 ne and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinom
 a\nEstimated primary completion: 31 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07902713
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875907-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Gemcitabine: Phase 1 readout est. (NCT07875907)
DESCRIPTION:Gemcitabine\, phase 1\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Repurposing Mefloquine for Pancreatic Cancer Treatment\nEstimated prima
 ry completion: January 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07875907
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897644-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06897644)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuati
 on of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanc
 ed Pancreatic Cancer.\nEstimated primary completion: 1 January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06897644
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02135042-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT02135042)
DESCRIPTION:Gemcitabine\, phase 2/3.\nStudy: Individualized Treatment in Tr
 eating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA\n
 Estimated primary completion: 31 January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02135042
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335497-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT07335497)
DESCRIPTION:Gemcitabine\, phase 1/2.\nStudy: CR-001 in Adult Participants W
 ith Locally Advanced or Metastatic Solid Tumors\nEstimated primary complet
 ion: February 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 emcitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07335497
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616362-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07616362)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patie
 nts With Resectable Borderline Pancreatic Ductal Adenocarcinoma.\nEstimate
 d primary completion: April 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07616362
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671534-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07671534)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Metronomic Gemcitabine\, Mitomyc
 in C\, and Thalidomide for Advanced Solid Tumors\nEstimated primary comple
 tion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemc
 itabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07671534
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04796220-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Gemcitabine: Phase 1 readout est. (NCT04796220)
DESCRIPTION:Gemcitabine\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Focused Ultrasound and Gemcitabine in Breast Cancer\nEstimated primar
 y completion: September 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04796220
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908979-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07908979)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Risk-Enabled Therapy After Initi
 ating EV/Pembro for Bladder Cancer\nEstimated primary completion: 1 Octobe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07908
 979
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06046794-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Gemcitabine: Phase na readout est. (NCT06046794)
DESCRIPTION:Gemcitabine\, phase na\, Pancreatic Ductal Adenocarcinoma.\nStu
 dy: Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic
  Pancreatic Adenocarcinoma Patients\nEstimated primary completion: Novembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06046
 794
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05538663-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT05538663)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Intravesical BCG vs GEMDOCE in N
 MIBC\nEstimated primary completion: 1 November 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05538663
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747740-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07747740)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Sequential Gemcitabine Plus Doce
 taxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-
 Invasive Bladder Cancer\nEstimated primary completion: 30 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07747740
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043972-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07043972)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Gemcitabine and Carboplatin Afte
 r Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastat
 ic Urothelial Carcinoma\nEstimated primary completion: 1 January 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07043972
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748611-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07748611)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and 
 Borderline Resectable Pancreatic Ductal Adenocarcinoma\, SMART-PANC Trial\
 nEstimated primary completion: 3 February 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07748611
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155629-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT07155629)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Cancer.\nStudy: Neoadjuvant 
 Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer\nEstimated p
 rimary completion: 31 August 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07155629
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096362-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07096362)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastat
 ic Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: 30 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7096362
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227065-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06227065)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Precise Chemoresection in Low-gr
 ade NMIBC Using Drug Screens in Patient-derived Organoids\nEstimated prima
 ry completion: 30 November 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06227065
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900789-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT07900789)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Cancer.\nStudy: HRS-4642 Com
 bined With Antitumor Agents for the Treatment of Perioperative Pancreatic 
 Cancer\nEstimated primary completion: 30 November 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07900789
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904819-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07904819)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Risk-Adapted Anlotinib and PD-L1
  for Locoregionally Advanced Nasopharyngeal Carcinoma\nEstimated primary c
 ompletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07904819
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783140-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06783140)
DESCRIPTION:Gemcitabine\, phase 2/3\, Pancreatic Cancer.\nStudy: Study of N
 ABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Can
 cer\nEstimated primary completion: 2 June 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06783140
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934331-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20310806
DTEND;VALUE=DATE:20310807
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05934331)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: A LM-302 Combination With Other 
 Anti-Tumor Therapies Phase ll Study\nEstimated primary completion: 6 Augus
 t 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05934
 331
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714604-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06714604)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LA
 PC\nEstimated primary completion: 31 December 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06714604
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322263-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20330101
DTEND;VALUE=DATE:20330102
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07322263)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Intravesical GEM/DOCE for HR BCG
 -Unresponsive NMIBC\nEstimated primary completion: 1 January 2033. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07322263
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528768-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20340601
DTEND;VALUE=DATE:20340602
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07528768)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: HEADWATERS: Gemcitabine vs Pacli
 taxel in Metastatic Triple-Negative Breast Cancer in Women of African Ance
 stry.\nEstimated primary completion: 1 June 2034. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07528768
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-7671@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Gemcitabine\, phase 2.\nStudy: Study to Investigate Outcome of 
 Individualized Treatment in Patients With Metastatic Colorectal Cancer\nEs
 timated primary completion: 31 December 2038. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
